Novavax Inc vs Veeva Systems — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Veeva Systems trades at $260.88 (market cap $42.88B). The key difference: Veeva Systems is far larger — about 25.5× Novavax Inc's market cap. Which is the better fit depends on your goals.
| NVAX | VEEV | |
|---|---|---|
Market Cap | $1.68B | $42.88B |
Sector | Health | Technology |
52-Week High | $11.19 | $306.22 |
52-Week Low | $6.22 | $151.43 |
Enterprise Value | $1.26B | $35.79B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →